Lainez Romeo, Parrino Gene, Bates Michael
Division of Cardiothoracic Surgery, Department of Surgery, Ochsner Clinic Foundation, New Orleans, LA.
Ochsner J. 2010 Winter;10(4):241-4.
The HeartMate II is an axial-flow left ventricular assist device that is approved for the treatment of advanced heart failure as a bridge to transplant or destination therapy. Despite the success of this device, right ventricular failure remains a persistent problem in most studies. Right ventricular dysfunction is usually defined as the need for right heart mechanical support or the persistent requirement for inotropes to support right heart function beyond 14 days. Over 21 months, 45 patients with end-stage heart disease underwent placement of the HeartMate II at our institution. This continuous cohort of patients underwent a retrospective review to evaluate the incidence of right heart failure. The perioperative survival was 91% with no incidents of mechanical support for the right ventricle and no requirements for inotropes beyond 14 days. This survival was consistent to beyond 1 year at the time of the study, and 18% of patients underwent heart transplant with 100% survival.
HeartMate II是一种轴流左心室辅助装置，已被批准用于治疗晚期心力衰竭，作为移植桥梁或终末治疗。尽管该装置取得了成功，但在大多数研究中，右心室衰竭仍然是一个持续存在的问题。右心室功能障碍通常定义为需要右心机械支持或持续需要使用正性肌力药物来维持右心功能超过14天。在21个多月的时间里，45例终末期心脏病患者在我们机构接受了HeartMate II植入手术。对这一连续队列的患者进行了回顾性分析，以评估右心衰竭的发生率。围手术期生存率为91%，未发生右心室机械支持事件，且超过14天后无需使用正性肌力药物。在研究时，这种生存率持续超过1年，18%的患者接受了心脏移植，生存率为100%。
